BridgeMD
New treatment option for ST Segment Elevation Myocardial Infarction (STEMI)
Official title Early Beta Blocker Administration in STEMI Patients With SCAI B Status
ClinicalTrials.gov ID: NCT06967194
What this study is testing
What is Metoprolol (MET)?
Metoprolol (MET) is an investigational medicine, given as an once-daily pill taken by mouth, being studied as a potential treatment for st segment elevation myocardial infarction (stemi).
Also referred to as metoprolol 25mg.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- This study is looking at how a medication called beta-blockers (metoprolol) affects patients with a heart attack (STEMI) who are in the cardiac intensive care unit. When patients are admitted to the unit, they will be randomly placed in one of two groups.
- You might receive a placebo (an inactive treatment) instead of the study drug, decided by chance. You may not know which one you got.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- Diagnosis of ST-segment elevation myocardial infarction (STEMI) confirmed by ECG, clinical signs, and coronary catheterization.
- Post-catheterization patients classified as SCAI B upon admission to the unit, defined by the presence of tachycardia and/or hypotension without...
- Age 18 years or older.
- Mentally competent to provide informed consent, understand the study procedures, and comply with medical recommendations.
You likely can't join if
- Pregnancy.
- Inability to provide informed consent.
- Evidence of pulmonary edema.
- Bradycardia (heart rate \<60 beats per minute).
- PR interval \>240 milliseconds.
- Second- or third-degree atrioventricular (AV) block.
See the full eligibility criteria
- Diagnosis of ST-segment elevation myocardial infarction (STEMI) confirmed by ECG, clinical signs, and coronary catheterization.
- Post-catheterization patients classified as SCAI B upon admission to the unit, defined by the presence of tachycardia and/or hypotension without signs of hypoperfusion (i.e., normal lactate levels, normal capillary...
- Age 18 years or older.
- Mentally competent to provide informed consent, understand the study procedures, and comply with medical recommendations.
- Pregnancy.
- Inability to provide informed consent.
- Evidence of pulmonary edema.
- Bradycardia (heart rate \<60 beats per minute).
- PR interval \>240 milliseconds.
- Second- or third-degree atrioventricular (AV) block.
- Active asthma.
- Known hypersensitivity to metoprolol.
The study team makes the final eligibility decision.
Where it's taking place
- Tel Aviv, Israel
Compensation & support
Compensation mentioned.
ClinicalTrials.gov doesn't provide a reliable structured field for payment or travel support - confirm details with the study team.
Questions & answers
Do participants get paid in this trial?
This study's listing includes signals that participants may be compensated or receive a stipend. Amounts vary and are set by the study team - confirm the details with them.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Tel Aviv, Israel. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.